It is currently Wed Jun 29, 2016 2:52 pm

News News of Drug Pipeline

Site map of Drug Pipeline » Forum : Drug Pipeline

A board to discuss future MS therapies in early stage (Phase I or II) trials.

p75NTR

Mentions other brain disease, so I'm assuming MS included.

The really interesting bit is:

"In further tests, the research team discovered that the compounds can also inhibit the death of oligodendrocytes, the cells in the central nervous system that form myelin, the insulating sheath surrounding nerve cells.

Normally, oligodendrocytes die when exposed to proneurotrophins – precursor forms of neurotrophins that have been implicated as agents of tissue damage in multiple sclerosis, spinal cord injury and ...
Read more : p75NTR | Views : 1450 | Replies : 0


Extracorporeal photochemotherapy

Never heard of this treatment before.




Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis.

Neurol Sci. 2006 Apr;27(1):24-32.
Cavaletti G, Perseghin P, Dassi M, Cavarretta R, Frigo M, Caputo D, Stanzani L, Tagliabue E, Zoia C, Grimaldi M, Isella V, Rota S, Ferrarese C, Frattola L.
D.N.T.B., University of Milano-Bicocca, Via Cadore 48, I-20052, Monza (MI), Italy.

Extracorporeal photochemotherapy (ECP) is an immunomodulating procedure consisting of ...
Read more : Extracorporeal photochemotherapy | Views : 1551 | Replies : 1


AlphaRX

AlphaRx Enters a Collaboration to Develop Novel Compounds for Central Nervous System Disorders

AlphaRx and PharmaSeed Collaborate to Develop New Drugs From a New Class of Small Molecules for the Potential Treatment of Central Nervous System Disorders Such as Stroke and Multiple Sclerosis.

AlphaRx Inc., an emerging biopharmaceutical company, announced today that it has entered into a collaboration with PharmaSeed Ltd. of Israel, a bio-pharmaceutical company specializing in drug discovery and early development phases for ...
Read more : AlphaRX | Views : 1230 | Replies : 0


Winter_2006_Progress_Summary from MRF

I had mailed Myelin Reasearch Foundation (MRF) about their winter progress update on research, since i didn't find them on their website. They replied within a day. Below is their response.

I was not able to upload the PDF document they had mailed me, so i am just adding the contents by copy & paste
-------------------------------------------------------------

Hello Gopi,

I'm responding to your inquiry about research progress updates. We are having trouble updating our website, so ...
Read more : Winter_2006_Progress_Summary from MRF | Views : 1395 | Replies : 0


Epratuzumab

Another one that's in phase III for lupus and they are talking about testing in other autoimmune diseases, including MS.



Immunomedics licenses drug to UCB

MAY. 10 - Business Week - Shares of Immunomedics Inc. jumped Wednesday when the biotech company said it agreed to license its lead product to Belgian biotech drug maker UCB for the treatment of immune system diseases.

Immunomedics shares rose 42 cents, or almost 15 percent, to $3.28 in morning ...
Read more : Epratuzumab | Views : 1653 | Replies : 1


Cytoxan and Novantrone

A research paper on Cytoxan and Novantrone.

<shortened url>

Both these treatments are cancer treatments. And also Campath and Caldribine are cancer drugs. This might be a stupid question - but what is cancer? Who says that MS isn't a blood cancer? It just seems odd that cancer treatments have some effect?

Ian
Read more : Cytoxan and Novantrone | Views : 1740 | Replies : 4


RPI-78M

Sounds like they are going to be starting a phase I/II MS trial soon.



Nutra Pharma Announces Approval to Start Late Phase II Human Trials in England

05/09/2006 -- Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that their holding, ReceptoPharm, has received approval from the Medicines Health and Regulatory Agency (MHRA) for its application of human clinical trials for the treatment of Adrenomyeloneuropathy (AMN). The ...
Read more : RPI-78M | Views : 1524 | Replies : 0


CF101

This is primarily in testing for RA, but they are planning trials in MS patients too...



CanFite BioPharma aims to raise NIS 50 million

May 9, 2006 - Israel Business Arena Via Thomson Dialog NewsEdge - Drug development company Can Fite BioPharma Ltd. published a draft flotation prospectus on Sunday for the raising of NIS 30 million and a further NIS 20 million in a future offering through the exercising of warrants. Founded in 2000 ...
Read more : CF101 | Views : 1290 | Replies : 0


Rituxin

Just for information:

I've been corresponding with my 'good' neuro about EBV and MS. I mentioned that some PP sufferers on another site were reporting good results from Rituxin (anectodal stuff, but many claimed progression had been halted).

This neuro said he was hopeful about Rituxin as it targets B-cells - one of the places where EBV lives. Just his opinion - but it will be interesting to see if the trial results (interim results) ...
Read more : Rituxin | Views : 1536 | Replies : 0


nutrition

From early trial research it seems that it is possible to stop/slow the advance of MS from nutritional inputs. (Not vitamin or mineral supplements or any "left-field" products; food based only, normal produce) Additionally, these inputs lessen the severity of tremor related strikes and fatigue related to tremor related strikes. Seeking participants in larger clinical trial. Diet inputs only, no experimental drugs or drug regimes. Localized areas only.
Read more : nutrition | Views : 1319 | Replies : 0


 

Login  •  Register


Statistics

Total posts 232979 • Total topics 24952 • Total members 16088


Contact us | Terms of Service